Fintel reports that on January 28, 2025, Jones Trading initiated coverage of OnKure Therapeutics (NasdaqGM:OKUR) with a Buy recommendation. Analyst Price Forecast Suggests 608.90% Upside As of January ...

In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on OnKure Therapeutics (OKUR – Research Report). The company’s ...

JonesTrading analyst Soumit Roy initiated coverage with a Buy rating on OnKure Therapeutics (OKUR – Research Report) today and set a price target of $32.00. The company’s shares closed today ...

Nov. 25, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology ...

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...

NBA All-Star event broke tradition with a fresh format, swapping the classic East vs. West showdown for a mini-tournament ...

Grant funds research on cilia's role in OCNDS, aiming to uncover key molecular changes and accelerate future treatment breakthroughs.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...